A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2 - Protocol A

Completed · Phase 3 · Has a placebo group

Conditions studied: Macular Telangiectasia Type 2 (MacTel)

In brief

This study is a phase 3, randomized, multi-center study to evaluate the efficacy and safety of the NT-501 implants in participants with macular telangiectasia type 2.

Key facts

Study ID
NCT03316300
Run by
Neurotech Pharmaceuticals
People needed
120
Starts
2017-11-24
Expected to finish
2022-09-23
Last updated by the study team
2024-09-24

Who can join

Age: 21 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.